Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490060 · ClinicalTrials.gov registry record · NA
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT01490060: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT01490060 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490060, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how different doses of fosaprepitant may effect how ifosfamide-based chemotherapy is absorbed by the body. Researchers also want to learn if fosaprepitant can help to control or prevent delayed nausea and/or vomiting that may be caused by chemotherapy. The safety of this drug will also be studied. Fosaprepitant is designed to block the natural substance in the brain that causes nausea and vomiting. This may help to prevent and/or control nausea and vomiting caused by chemotherapy.
Interventions
- DRUG Doxorubicin
- DRUG Dexamethasone
- DRUG Fosaprepitant
- DRUG 5HT3 receptor antagonist
- DRUG Ifosfamide-based chemotherapy (AI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01490060
The ClinicalTrials.gov registry entry for NCT01490060 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT01490060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01490060 about?
NCT01490060 is a clinical study titled "Fosaprepitant in Patients Receiving Ifosfamide-based Regimen". The goal of this clinical research study is to learn how different doses of fosaprepitant may effect how ifosfamide-based chemotherapy is absorbed by the body. Researchers also want to learn if fosaprepitant can help to control or prevent delayed nausea and/or vomiting that may be caused by chemothe...
What is the current status of trial NCT01490060?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2012-05. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01490060?
The interventions under investigation include: Doxorubicin (DRUG), Dexamethasone (DRUG), Fosaprepitant (DRUG), 5HT3 receptor antagonist (DRUG), Ifosfamide-based chemotherapy (AI) (DRUG).
Who is sponsoring clinical trial NCT01490060?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.